Novartis: Multiple Sclerosis, Chronic Progressive trials

The registry lists 16 Multiple Sclerosis, Chronic Progressive studies with Novartis as lead sponsor. 1 are open to participants now and 4 have results posted.

Phase 1 1Phase 2 2Phase 3 3Phase 4 1No phase 10(a study in two phases counts in both)

Studies

Open to participants first, then studies with results posted, then the rest; newest registration first within each.

• A Study to Evaluate the Efficacy and Safety of Remibrutinib in Secondary Progressive Multiple SclerosisRecruitingNCT07225504Phase 3
• Exploring the Immune Response to SARS-CoV-2 modRNA Vaccines in Patients With Secondary Progressive Multiple Sclerosis (AMA-VACC)CompletedNCT04792567Phase 4Results posted
• A 12 Week Randomized Open Label Parallel Group Multicenter Study to Evaluate Bioequivalence of 20 mg Subcutaneous Ofatumumab Injected by Pre-filled Syringe or Autoinjector in Adult RMS PatientsCompletedNCT03560739Phase 2Results posted
• Exploring the Efficacy and Safety of Siponimod in Patients With Secondary Progressive Multiple Sclerosis (EXPAND)CompletedNCT01665144Phase 3Results posted
• This Was an Open-label, Single-arm Extension Study (CFTY720D2306E1) to a Double-blind, Randomized Multicenter, Placebo-controlled, Parallel-group Core Study (CFTY720D2306) in PPMS.TerminatedNCT00731692Phase 3Results posted
• A Real-world Study About the Impact of Siponimod Treatment on Secondary Progressive Multiple Sclerosis Patients in RussiaCompletedNCT07168694
• Real World Effectiveness, Persistence, Tolerability, and Safety of Ofatumumab in Clinical PracticeCompletedNCT06737419
• Open-label, Multi-center, Phase I/II Study to Assess Safety, Disease Progression and Cellular Kinetics Following YTB323 Administration in Participants With Non-active Progressive Multiple Sclerosis (PMS)Active, not recruitingNCT06675864Phase 1/2
• A Real-world Study to Assess the Use of Siponimod in Spain to Treat Patients With Secondary Progressive Multiple SclerosisCompletedNCT06588387
• Study to Assess Changes in Immunoglobulins in Patients With Relapsing Multiple Sclerosis Treated With Anti-CD20 TherapiesCompletedNCT06526000
• A Study to Assess the Effectiveness and Safety of Mayzent in Chinese Patients With Relapsing Forms of Multiple SclerosisCompletedNCT06395909
• Mayzent (Siponimod) Onboarding of Secondary Progressive Multiple Sclerosis (SPMS) Patients With MSGoCompletedNCT05826028
• Impact of Mayzent on aSPMS Patients in a Long-term NIS in ItalyCompletedNCT05376579
• Swiss Study of the Impact of Mayzent on SPMS Patients in a Long-term Non-interventional StudyTerminatedNCT04895202
• Long Term Special Drug Use-results Surveillance for Mayzent in SPMS PatientsCompletedNCT04593927
• Managed Access Program (MAP) for Patients Diagnosed With Secondary Progressive Multiple Sclerosis With Active DiseaseNo longer availableNCT04540861